Mammalian target of rapamycin inhibitors for prolonged secondary prevention of nonmelanoma skin cancer in solid organ transplant recipients.
Carcinoma, Basal Cell
/ etiology
Carcinoma, Squamous Cell
/ etiology
Humans
Immunosuppressive Agents
/ adverse effects
MTOR Inhibitors
/ therapeutic use
Organ Transplantation
/ adverse effects
Retrospective Studies
Secondary Prevention
Sirolimus
/ therapeutic use
Skin Neoplasms
/ etiology
TOR Serine-Threonine Kinases
/ antagonists & inhibitors
immunosuppression
mammalian target of rapamycin inhibitors
nonmelanoma skin cancers
solid-organ transplant recipients
squamous cell carcinoma
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
30
05
2022
received:
24
11
2021
accepted:
16
06
2022
pubmed:
19
6
2022
medline:
9
8
2022
entrez:
18
6
2022
Statut:
ppublish
Résumé
Immunosuppressive agents are essential for graft survival in solid-organ transplant recipients (SOTRs), but they have substantial durable side effects, including a higher incidence of aggressive nonmelanoma skin cancers (NMSCs). Hitherto, only one class of immunosuppressants, mammalian target of rapamycin inhibitors (mTORi), may inhibit skin tumor formation, however their durable effectiveness is controversial. To evaluate the sustained effectiveness of mTORi in reducing NMSCs' incidence in SOTRs, a retrospective study was conducted in a specialized dermatology clinic for SOTRs of a tertiary university-affiliated medical center. SOTRs with a history of at least one histologically proven NMSC were followed for 6 years: 3 years after transplantation, before initiation of mTORi, and 3 years under mTORi treatment. The cohort consisted of 44 SOTRs. Treatment with mTORi was initiated on average 6.27 (3.34-6.34) years following transplantation. In the 3 years before mTORi treatment initiation, the mean number of new NMSCs per patient was 2.11 (1-14). This value decreased to 1.2 (0-19) in the 3 years under mTORi treatment (p = 0.0007). Analysis by NMSC type yielded a significant decrease in both SCCs and BCCs. This study found that mTORi are effective for prolonged secondary prevention of NMSCs in SOTRs.
Substances chimiques
Immunosuppressive Agents
0
MTOR Inhibitors
0
TOR Serine-Threonine Kinases
EC 2.7.11.1
Sirolimus
W36ZG6FT64
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15649Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Krynitz B, Edgren G, Lindelöf B, et al. Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008-a Swedish population-based study. Int J Cancer. 2013;132(6):1429-1438. doi:10.1002/ijc.27765
Schrem H, Barg-Hock H, Strassburg CP, Schwarz A, Klempnauer J. Aftercare for patients with transplanted organs. Dtsch Aerzteblatt Int. 2009;106(9):148-156. doi:10.3238/arztebl.2009.0148
Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348(17):1681-1691. doi:10.1056/NEJMra022137
Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol. 2002;47(1):1-17; quiz 18-20. doi:10.1067/mjd.2002.125579
Jain A, Khanna A, Molmenti EP, Rishi N, Fung JJ. Immunosuppressive therapy. Surg Clin North Am. 1999;79(1):59-76. doi:10.1016/s0039-6109(05)70007-4
Hollenbeak CS, Todd MM, Billingsley EM, Harper G, Dyer AM, Lengerich EJ. Increased incidence of melanoma in renal transplantation recipients. Cancer. 2005;104(9):1962-1967. doi:10.1002/cncr.21404
Euvrard S, Kanitakis J, Pouteil-Noble C, et al. Aggressive squamous cell carcinomas in organ transplant recipients. Transplant Proc. 1995;27(2):1767-1768. https://pubmed.ncbi.nlm.nih.gov/7725494/
Adamson R, Obispo E, Dychter S, et al. High incidence and clinical course of aggressive skin cancer in heart transplant patients: a single-center study. Transplant Proc. 1998;30(4):1124-1126. doi:10.1016/s0041-1345(98)00178-x
Geissler EK. Skin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer? Transplant Res. 2015;2015(4):4-9. doi:10.1186/s13737-014-0022-4.eCollection
Ciuffreda L, Di Sanza C, Incani UC, Milella M. The mTOR pathway: a new target in cancer therapy. Curr Cancer Drug Targets. 2010;10(5):484-495. doi:10.2174/156800910791517172
Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation. 2002;73(10):1565-1572. doi:10.1097/00007890-200205270-00008
Law BK. Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol. 2005;56(1):47-60. doi:10.1016/j.critrevonc.2004.09.009
Otley CC, Coldiron BM, Stasko T, Goldman GD. Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants. Arch Dermatol. 2001;137(4):459-463.
Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation. 2005;80(7):883-889. doi:10.1097/01.tp.0000184006.43152.8d
Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant. 2004;18(4):446-449. doi:10.1111/j.1399-0012.2004.00188.x
Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation. 2004;77(5):760-762. doi:10.1097/01.tp.0000115344.18025.0b
Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol. 2006;17(2):581-589. doi:10.1681/ASN.2005090993
Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs. 2007;67(8):1167-1198. doi:10.2165/00003495-200767080-00006
Salgo R, Gossmann J, Schöfer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant. 2010;10(6):1385-1393. doi:10.1111/j.1600-6143.2009.02997.x Epub 2010 Feb 1.
Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009;87(2):233-242. doi:10.1097/TP.0b013e3181927a41
Ulrich C, Kanitakis J, Stockfleth E, Euvrard S. Skin cancer in organ transplant recipients--where do we stand today? Am J Transplant. 2008;8(11):2192-2198. doi:10.1111/j.1600-6143.2008.02386.x
Stasko T, Brown MD, Carucci JA, et al. Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg. 2004;30(4 Pt 2):642-650. doi:10.1111/j.1524-4725.2004.30150.x
Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med. 2005;352(13):1317-1323. doi:10.1056/NEJMoa042831
Campbell SB, Walker R, Tai SS, Jiang Q, Russ GR. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant. 2012;12(5):1146-1156. doi:10.1111/j.1600-6143.2012.04004.x
Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med. 2012;367(4):329-339. doi:10.1056/NEJMoa1204166
Hoogendijk-van Den Akker JM, Harden PN, Hoitsma AJ, et al. Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus. J Clin Oncol. 2013;31(10):1317-1323. doi:10.1200/JCO.2012.45.6376
Alter M, Satzger I, Schrem H, Kapp A. Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients. J Dtsch Dermatol Ges. 2014;12(6):480-488. doi:10.1111/ddg.12355
Euvrard S, Boissonnat P, Roussoulières A, et al. Effect of everolimus on skin cancers in calcineurin inhibitor-treated heart transplant recipients. Transpl Int. 2010;23(8):855-857. doi:10.1111/j.1432-2277.2009.01010.x
Alberú J, Pascoe MD, Campistol JM, et al. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation. 2011;92(3):303-310. doi:10.1097/TP.0b013e3182247ae2
Murray SL, Daly FE, O'Kelly P, et al. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients. Ren Fail. 2020;42(1):607-612. doi:10.1080/0886022X.2020.1785499
Yakupoglu YK, Buell JF, Woodle S, Kahan BD. Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy. Transplant Proc. 2006;38(2):358-361. doi:10.1016/j.transproceed.2006.01.019
Opelz G, Unterrainer C, Süsal C, Döhler B. Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients. Nephrol Dial Transplant. 2016;31(8):1360-1367. doi:10.1093/ndt/gfw088
Chow RY, Levee TM, Kaur G, Cedeno DP, Doan LT, Atwood SX. MTOR promotes basal cell carcinoma growth through atypical PKC. Exp Dermatol. 2021;30(3):358-366. doi:10.1111/exd.14255